Modality
Gene Editing
MOA
PI3Ki
Target
IL-17A
Pathway
Checkpoint
FL
Development Pipeline
Preclinical
~May 2013
→ ~Aug 2014
Phase 1
~Nov 2014
→ ~Feb 2016
Phase 2
~May 2016
→ ~Aug 2017
Phase 3
Nov 2017
→ Dec 2028
Phase 3Current
NCT03999075
656 pts·FL
2017-11→2028-12·Completed
NCT03383515
1,550 pts·FL
2023-04→TBD·Not yet recruiting
NCT04789776
419 pts·FL
2022-01→2028-01·Recruiting
2,625 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-01-111.8y awayPh3 Readout· FL
2028-12-262.7y awayPh3 Readout· FL
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P3
Complet…
P3
Recruit…
P3
Not yet…
Catalysts
Ph3 Readout
2028-01-11 · 1.8y away
FL
Ph3 Readout
2028-12-26 · 2.7y away
FL
RecruitingCompletedNot yet recruiting|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03999075 | Phase 3 | FL | Completed | 656 | SRI-4 |
| NCT03383515 | Phase 3 | FL | Not yet recr... | 1550 | ACR20 |
| NCT04789776 | Phase 3 | FL | Recruiting | 419 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| REG-3155 | Regeneron | Phase 1/2 | MDM2 | |
| SRP-3270 | Sarepta | Phase 1/2 | SGLT2 |